

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 35/14	A1	(11) International Publication Number: WO 97/34614 (43) International Publication Date: 25 September 1997 (25.09.97)
(21) International Application Number: PCT/CA97/00188 (22) International Filing Date: 19 March 1997 (19.03.97) (30) Priority Data: 08/618,560 20 March 1996 (20.03.96) US (71) Applicant: THERATECHNOLOGIES INC. [CA/CA]; 5e étage, 630, boulevard René-Lévesque Ouest, Montréal, Québec H3B 1S6 (CA). (72) Inventors: BRAZEAU, Paul; 4054, avenue du Parc-Lafontaine, Montréal, Québec H2L 3M8 (CA). ABRIBAT, Thierry; 3539, de Bordeaux, Montréal, Québec H2K 3Z2 (CA). IBEA, Michel; 1158 Visitation Street, Montréal, Québec H2L 3B4 (CA). BOUSHIRA, Michèle; 4054, avenue du Parc-Lafontaine, Montréal, Québec H2L 3M8 (CA). (74) Agent: COTE, France; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PROCESS FOR THE PREPARATION OF PLATELET GROWTH FACTORS EXTRACT FOR WOUND HEALING COMPOSITIONS (57) Abstract The present invention relates to a process for the preparation of porcine platelet-extract containing matured growth factors, which comprises the steps of: a) centrifuging whole porcine blood at about 1000 g to about 5000 g to isolate the platelets from the platelet-rich-plasma; b) resuspending the isolated platelets of step a) in Plasma-Lyte A and centrifuging to concentrate the platelets; c) washing the concentrated platelets of step b); d) lyophilizing the washed platelets of step c) whereby causing lysis of the platelets and producing the platelet extract in optimal amount. Compositions comprising the platelet-extract are used for the promotion of wound healing.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PROCESS FOR THE PREPARATION OF PLATELET GROWTH FACTORS EXTRACT
FOR WOUND HEALING COMPOSITIONS

BACKGROUND OF THE INVENTION

5 (a) Field of the Invention

The invention relates to a process for the production of platelet extracts derived from whole porcine blood and their clinical uses in wound dressing.

(b) Description of Prior Art

10 Wound healing is a complex cascade of cellular and biochemical events which lead to wound closure and repair of tissues. Three successive phases are classically distinguished in the wound healing process:

- 15 1) the inflammatory phase, which corresponds to increased vascular permeability and migration of leukocytes and macrophages;
- 2) the proliferative phase, characterized by fibroblast proliferation and collagen synthesis, resulting in granulation tissue formation; and
- 20 3) the remodeling phase, where collagen and granulation tissue rearrangements results in scar resorption.

The very first event which usually occurs in a wound is blood extravasation, that results in platelet aggregation and impregnation of the wound with platelet and serum constituents. Among these constituents are polypeptide growth factors, which are known to play a major role in tissue regeneration. Platelet α granules, which are released by aggregated platelets, are one of the richest physiological source of platelet-derived growth factor (PDGF) and transforming growth factor β (TGF β), while serum contains high amounts of insulin-like growth factor I (IGF-I), IGF-II and their binding proteins (IGF-BPs) (Strovbant P & Waterfield MD, Endo. J., 1984, 2:2963-2967; Assoian RK et al., J. Biol.

25
30
35

Chem., 1983, 258:7155-7160; Sara VR et al., *Physiol. Rev.*, 1990, 70:591-614).

PDGFs include PDGF, platelet derived angiogenesis factor (PDAF), TGF β and platelet-factor-4 (PF-4), which is a chemoattractant for neutrophils (Knighton et al., *In Growth Factors and Other Aspects of Wound Healing: Biological and Clinical Implications*, Alan R. Liss, Inc., pp. 319-329 (1988)). PDGF is a mitogen and chemoattractant for fibroblasts and smooth muscle cells and is a stimulator of protein synthesis in cells of mesenchymal origin, including fibroblasts and smooth muscle cells. PDGF is also a nonmitogenic chemoattractant for endothelial cells.

TGF β is a chemoattractant for macrophages and monocytes. Depending upon the presence or absence of other growth factors, TGF β increases the tensile strength of healing dermal wounds. TGF β also inhibits endothelial cell mitosis, and stimulates collagen and glycosaminoglycan synthesis by fibroblasts.

Other growth factors, such as EGF, TGF α , the HBGFs and osteogenin, are also important in wound healing. EGF, which is found in gastric secretions and saliva, and TGF α , which is made by both normal and transformed cells, are structurally related and may recognize the same receptors, which mediate cell proliferation on epithelial cells. Both factors accelerate re-epithelialization of skin wounds.

The *in vivo* mode of action of these growth factors involves chemoattraction at the wound site, cell proliferation and collagen synthesis. One very interesting feature of these products is that some of them, namely PDGF and IGFs, work synergistically in stimulating wound repair (Lynch SE et al., *J. Clin. Invest.*, 1989, 84:640-646; Greenhalgh DG et al., *Wound. Rep. Reg.*, 1993, 1:54-62).

Growth factors are, therefore, potentially useful for specifically promoting wound healing and tissue repair. The addition of exogenous growth factors to a wound has been shown to increase the rate at which the wound is closed, the number of cells in the healing area, the growth of blood vessels, the total rate of deposition of collagen, and strength of the scar (Carter et al., in *Growth Factors and Other Aspects of Wound Healing: Biological and Clinical Implications*, Alan R. Liss, Inc., pp. 303-317 (1988)).

Platelet-derived wound healing formula (PDWHF), a platelet extract which is in the form of a salve or ointment for topical application, has been described by Knighton et al. (*Ann. Surg.*, 1986, 204: 322-330). Knighton et al. (*Ann. Surg.*, 1986, 204: 322-330 & *In Growth Factors and Other Aspects of Wound Healing: Biological and Clinical Implications*, Alan R. Liss, Inc., pp. 319-329 (1988)) describe a process for the preparation of a platelet-derived wound healing composition by centrifuging platelets and treating them with thrombin to stimulate the production of a releasate, which can be combined with collagen. Knighton et al. obtain a platelet-derived releasate having a limited concentration of growth factors with high concentration of albumin (9.9%), which limits its clinical uses. Also, this platelet-derived releasate contains essentially non-mature growth factors due to the use of thrombin to break apart the platelets and release their content.

Clinical evaluation of recombinant growth factors are underway but it remains so far uncertain whether the therapeutic benefit of these drugs will pay for their high cost of production specially if used in combination.

Autologous human platelet derived wound healing formula, made of thrombin activated platelet α gran-

ules, has also been shown to induce the healing of chronic ulcers, thus indicating that growth factor extracts may constitute an advantageous alternative to the use of recombinant growth factors if proven to be economically extractable.

It would be highly desirable to be provided with a economical and easy to carry out process for the isolation of contamination-free blood derived platelet extract for use in a wound dressing composition. Such a blood derived platelet extract should be absolutely free of Hepatitis B and HIV contaminants.

It would be highly desirable to be provided with a process for the isolation of platelet extract containing matured growth factors with minimal albumin concentration (0.4%) and improved contents of wound healing substances (growth factors, fibronectin, thrombospondin, etc...), which would be derived from whole porcine blood, and suitable for use in a wound dressing composition.

It would be highly desirable to be provided with a method for the promotion of wound healing of a patient which comprises the topical administration of the pharmaceutical composition on the wound of the patient.

SUMMARY OF THE INVENTION

One aim of the present invention is to provide a process for the isolation of platelet extract containing matured growth factors at a concentration such that it contains minimal albumin and optimal growth factors, fibronectin and thrombospondin.

Another aim of the present invention is to provide for a process which results in an improved platelet extract containing matured growth factors and only traces of albumin.

In accordance with one embodiment of the present invention, there is provided a process for the preparation of porcine platelet-extract containing matured growth factors, which comprises the steps of:

- 5 a) centrifuging whole porcine blood at about 1000g to about 5000g to isolate the platelets from the platelet-rich-plasma;
- b) resuspending the isolated platelets of step a) in Plasma-Lyte A and centrifuging to concentrate the platelets;
- 10 c) washing the concentrated platelets of step b);
- d) lyophilizing the washed platelets of step c); whereby causing lysis of the platelets and producing the platelet extract.

15 In accordance with another embodiment of the present invention, the process further includes a step of resuspension in pure water after step d), wherein the lyophilized platelets are resuspended.

 In accordance with another embodiment of the present invention, there is provided a pharmaceutical composition for promoting wound healing, which contains an effective concentration of a platelet extract prepared according to the process of the present invention, wherein the platelet extract contains matured growth factors, thrombospondin, fibronectin and minimal albumin; in association with a pharmaceutically acceptable carrier. Such a pharmaceutical composition has a platelet extract concentration between 10^7 to 10^{12} platelet equivalent/ml with only traces of albumin proteins.

30 In accordance with another embodiment of the present invention, there is provided the use of the pharmaceutical composition of the present invention for the promotion of wound healing of a patient.

For the purpose of the present invention the following terms and abbreviations are defined below.

"PRP" is intended to mean a platelet-rich-plasma, preferably of porcine origin prepared by low speed centrifugation in order to pellet and remove erythrocytes and leukocytes.

"PE" is intended to mean a platelet extract.

"PPP" is intended to mean a platelet-poor-plasma.

10

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 illustrates the preparation of porcine platelet extracts in accordance with one embodiment of the present invention;

15

Fig. 2 illustrates the preparation of platelet reference (PTRF) according to the procedure of Knighton;

20

Fig. 3 illustrates the elution profile on column Protein Pak SW™ (8.0 x 300) of different molecular weight markers;

Fig. 4 illustrates the elution profile on column Protein Pak SW™ (8.0 x 300) of platelet reference (PTRF) according to the procedure of Knighton;

25

Fig. 5 illustrates the elution profile on column Protein Pak SW™ (8.0 x 300) of a porcine platelet extract (EP-PL-Lyte) in accordance with one embodiment of the present invention;

30

Fig. 6 illustrates the elution profile on column Protein Pak SW™ (8.0 x 300) of a porcine platelet extract (EP-95-11) in accordance with one embodiment of the present invention;

Fig. 7 illustrates the elution profile on YMC-Pak Column Diol-120™ of different molecular weight markers;

Fig. 8 illustrates the elution profile on YMC-Pak Column Diol-120™ of platelet reference (PTRF) according to the procedure of Knighton;

Fig. 9 illustrates the elution profile on YMC-Pak Column Diol-120™ of a porcine platelet extract (EP-PL-Lyte) in accordance with one embodiment of the present invention; and

Fig. 10 illustrates the elution profile on YMC-Pak Column Diol-120™ of a porcine platelet extract (EP-95-11) in accordance with one embodiment of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

The process of the present invention for the manufacture of porcine platelet extracts is new, simple and inexpensive. Moreover, the porcine origin of the blood, in accordance with the present invention, guarantees: 1) a total absence of potential transmission of human viral agents (Hepatitis, HIV, etc.); 2) the production of growth factors nearly 100% identical to their human counterparts and, 3) a reliable, largely available and highly reproducible source of raw material.

The process of the present invention results in an improved platelet extract containing matured growth factors and only traces of albumin.

The preferred embodiments of the process of the present invention are more specifically described as follows, which is intended to illustrate the invention rather than to limit its scope.

1. BLOOD EXTRACTS PREPARATION

1.1 Blood collection

For experimental purposes, porcine whole blood was used in accordance with the present invention due to its availability and its contamination-free character.

teristic. Thus, young Landrace, Yorkshire, male castrated 2 month-old piglets of 25 kg B.W. were purchased from a local breeder). They were housed for 2-5 days in our facilities with free access to water and food.

5 For blood collection, they were anaesthetized with ketamine hydrochloride (10 mg/kg BW), then with fluothane by intratracheal administration. A cannula was aseptically inserted into one carotid artery. Before animals were exsanguinated, 2 ml of heparin

10 saline was injected in the cannula system and the same volume was vacuumed out. About 450 ml of sterile blood was collected in each triple bag (CLX CPDA-1, sold by Miles Canada).

15 **1.2 Platelet-rich-plasma (PRP)**

The collected sterile whole porcine blood was centrifuged in its collection bag for about 4.5 min. at 1375g (BRAKE=3; Rotor JS-4.2; Beckman™ J6-B). The supernatant, platelet-rich-plasma (PRP), was collected

20 by emptying the content of the centrifuged bag in a second bag until the red blood cells are at about 1 cm of the top edge of the emptied bag.

1.3 Platelet concentrate (PC)

25 The collected platelet-rich-plasma (PRP) was immediately centrifuged in its storage bag for about 8 min. at 5000g (BRAKE=maximum; Rotor JS-4.2; Beckman™ J6-B). After centrifugation, the platelet-poor-plasma (PPP) was transferred to a third bag until maximum

30 removal of the PPP or when a volume of about 10 ml remains in the second bag containing the platelet concentrate. The PPP was discarded.

The second bag containing the platelet concentrate was resting on a weigh-bridge (Sartorius™ LC-4800-P). A bag of Plasma-Lyte A™ (Baxter) was connected to a secondary medication device, followed by a

35

septum and a needle of 18G x 1½. The needle was introduced through a membrane located in one of the bag's chimney. 48 g of Plasma-Lyte A™ was injected into the bag.

- 5 The platelet concentrate was left to rest for 2 hours and was then agitated overnight on a horizontal shaker (New Brunswick Scientific, model G20) at 25 RPM and 22°C.

10 **1.4 Washing of the platelet concentrate (PC)**

- The content of six (6) platelet concentrate bags were collected in a six-line Leukotrap™ bag (Miles Canada). Centrifuged for 15 min. at 180g (BRAKE=maximum; Rotor JS-4.2; Beckman™ J6-B). The
15 appendix of the bag containing the red blood cells residue was closed using the clamp which is usually used for retaining leukocytes. The bag was turned upside down, suspended and the supernatant was transferred in a six-line CLX bag (Miles Canada) using the
20 proximal line. The order of the lines used is always from the proximal to the distal.

- Centrifuged for 8 min. at 5000g (BRAKE=maximum; Rotor JS-4.2; Beckman™ J6-B). The bag was placed on a plasma press (Miles Canada) and the maximum of super-
25 natant was removed in a beaker. The line was closed using an aluminum ring.

- The bag containing the centrifuged platelet concentrate was placed on a weigh-bridge (Sartorius™ LC-4800-P) and was injected with 48g of Plasma-Lyte A™
30 using one line of the CLX bag. The bag opening was temporarily blocked using a hemostatic claw or an aluminum ring to prevent a reflux in the lines.

- The platelet concentrate was left to rest for one hour and was then agitated for about one hour or
35 until complete resuspension on a horizontal shaker (New Brunswick Scientific, model G20) at 25 RPM and 22°C.

The bag was placed on a weigh-bridge (Sartorius[™] LC-4800-P) and was injected with 360 g of Plasma-Lyte A[™] using one line of the CLX bag. Mixed well.

5 The content of the bag was transferred to a graduated cylinder for the cellular culture. The volume was measured. 1 ml is taken to a 5 ml polypropylene tube in a sterile manner. The platelets, red blood cells and white blood cells are counted. The total quantity of platelets obtained was calculated
10 along with a mean per bag of blood collected. For five extractions, a mean value of $57 \pm 13 \times 10^9$ platelets/bags was obtained.

The platelet concentrate was then transferred in sterile conical tubes of 250 ml. These were
15 centrifuged without the cover of the rotor for 20 min. at 2900g (BRAKE=maximum; Rotor JS-4.2; Beckman[™] J6-B).

1.5 Platelets extract (PE) preparation

The platelet residue was removed from the
20 supernatant and was resuspended at 1×10^{10} platelets/ml in picopure water at 4°C. This was frozen in thin layers using liquid nitrogen, and then lyophilized.

The lyophilized platelets were resuspended in
25 sterile picopure water at 4°C.

These were centrifuged in Oak Ridge tubes for 30 min. at 40 000g and 4°C (BRAKE=maximum; Rotor JA-20; Beckman[™] J2-21).

Aliquoted in 1, 2 or 5 ml and stored at -80°C.
30

2. ANALYTICAL PROCEDURES

Proteins were measured by a Lowry method (J. Biol. Chem., 1951, 193:265-275) using a commercial kit sold by Sigma Chemical (St. Louis, MO).

35 Platelet-derived growth factor (PDGF) was measured by radioimmunoassay using a commercial kit

(Amersham International, UK) according to the following procedure.

PORCINE PDGF RIA PROCEDURE

Tube #	Standard or sample	Buffer	^{125}I -PDGF-2 $\beta\beta$	Ab ₁ Raised in goat
1- Trace	—	—	100 μl	—
2- Background	—	400 μl	100 μl	—
3- Zero	—	300 μl	100 μl	100 μl
4- 0.044 ng/tube	100 μl	200 μl	100 μl	100 μl
5- 0.137 ng/tube	100 μl	200 μl	100 μl	100 μl
6- 0.410 ng/tube	100 μl	200 μl	100 μl	100 μl
7- 1.230 ng/tube	100 μl	200 μl	100 μl	100 μl
8- 3.700 ng/tube	100 μl	200 μl	100 μl	100 μl
9- 11.000 ng/tube	100 μl	200 μl	100 μl	100 μl
10- 33.000 ng/tube	100 μl	200 μl	100 μl	100 μl
11-100.000 ng/tube	100 μl	200 μl	100 μl	100 μl
12- unknown ng/tube	100 μl	200 μl	100 μl	100 μl

5 Incubation: 20 to 24 hours at 22°C.

Precipitation: 2nd antibody precipitation (100 μl)

50 μl 4% normal goat plasma and 50 μl donkey anti-goat gamma globulins (diluted 1 in 5 with buffer), vortex, leave 18 hrs or overnight at 22°C, centrifuge 35 mins at 3200 rpm, decant and count

10 Dilution of standard: Porcine PDGF 1 ng/ml frozen in aliquot of 500 μl (500 ng/500 μl)

1. 200 μl is added to 400 μl buffer = 33.3 ng/100 μl ;

2. A serial dilution is made by 1/3 for standard from 100ng/100 μl to 0.044ng/100 μl .

Dilution of Ab₁ (anti-hPDGF-BB, AB-220-NA):

1. Frozen in 40 μl aliquots of a dilution of 1/1;

15 2. 20 μl in 1980 μl of buffer make a dilution of 1/100. Take 100 μl of 1/100 Ab₁ in 16 μl buffer, make a final dilution of 1/80K.

Tracer: ^{125}I -PDGF₁ (Dupont) diluted in PDGF buffer so that 100 μl = 13 000 cpm.

According to the manufacturer's data, cross reactivity of porcine PDGF is 38% with the anti human PDGF antibody used in the kit. Results were therefore converted in porcine PDGF equivalent by dividing them by 0.38.

Transforming growth factor β 1 and β 2 were measured using the Quantikine test™ commercially available

(R and D Systems, Minnesota, U.S.A.). Before measurement, extracts were mixed 1:2 either in distilled water or in trifluoroacetic acid (TFA) 1%, incubated for 1 hour at room temperature, lyophilized and reconstituted with water to their initial volume. This procedure was conducted in order to determine if TGF β was present in extracts as an active or latent, high molecular weight form.

10 3. IN VITRO ASSAYS

3.1 Pig Anaesthesia

A pig of 25 kg \pm 2 kg was injected intramuscularly with ketamine (15mg/kg). After 5 to 10 min., the pig was tracheotomized, intubated and artificially ventilated using a mechanical respirator. The current volume was fixed at 15cc/kg and the respiratory frequency was maintained between 10 and 15 per min. to keep a Pa CO₂ between 35 and 45 mmHg. The anaesthesia was asserted with 1.5% to 2.0% fluothane.

20

3.2 Skin removal

The pig was placed in a decubitus position, the skin sections were removed from the postero-anterior region. This region was previously shaved, washed with compresses impregnated with cidex, rinsed with tap water and then abundantly sprayed with 70% ethanol.

Skin strips of 15 cm by 2.5 cm were removed using a sterile scalpel blade. The strips were bathed successively in 50ml sterile tubes containing 40ml 70% ethanol, then in sterile PBS (phosphate buffer saline) and finally in a sterile washing culture (DMEM, 5% penicillin-streptomycin, 125ug/ml fungizone).

30

3.3 Dig sti n method

Under the flux hood, the strips are immediately transferr d in a sterile petri of 145 cm² containing

35

100ml of washing culture medium. Each strips is cut in pieces of 2.5 cm by 2.0 cm using a scalpel blade and a sterile tissue tongs.

Pieces of tissue were then incubated in a washing medium for 60 min. at room temperature under the flux hood in order to sterilized the pieces in the culture medium containing antibiotics. The pieces were then washed in three successive baths of 100ml of sterile PBS in petri dishes.

In a digestion bottle of 250ml having a magnetic agitator, pieces of tissue were digested under agitation in 100ml of pronase at a concentration of 1mg/ml in DMEM, 1% penicillin-streptomycin in an incubator under 5% CO₂ atmosphere at 37°C for one hour.

After a one-hour digestion, the pronase enzyme was decanted and the tissue pieces were washed with washing medium. To complete the digestion, the tissue pieces were put back under agitation during 18 hours in 100ml of collagenase IV at a concentration of 300µ/ml in a DMEM medium, 1% penicillin-streptomycin.

3.4 Cell culture

After an 18-hour incubation, the cell suspension was then centrifuged in sterile tubes (50ml) for 5 min. at 800g in a table centrifuge. The supernatant was decanted and the cell residue was resuspended in a DMEM medium. A 50ul cell aliquot was mixed well with 10ml of Isoton II™ in a counting cupule. From this mix a 500ul volume is counted using a Coulter Counter ZM™ (Coulter Electronics of Canada Ltd.) which the counting bounds were previously fixed. The cells were then inseminated to a density of 50×10^6 in 175 cm² bottles containing 25ml of DMEM, 10% CFS (Calf Fetal Serum), 1% penicillin-streptomycin and were placed in an incubator at 37°C, 5% CO₂ and 100% humidity. When most of the

cells have adhered, about 4 hours after the insemination, the culture medium is then replaced, and also the following day. The cell adhesion was estimated at about 30%. The cells were then trypsinized each 2 days according to a dilution of $\frac{1}{4}$ of the cell residue per bottle.

3.5 Biological assays on porcine culture fibroblasts

The effect of the samples was systematically verified on the growth and the metabolism of porcine fibroblasts. This assay allows to detect if samples act upon the proliferation and the metabolism of cells (inhibition, stimulation or lethal effect). The samples effect was always compared to the effect of foetal veal serum of a concentration of 10% (positive control).

Experimental protocol of proliferation assay

Day 1: The assay was effected with Fibroblasts at passage 4. Thus, the fibroblasts which have come to passage 3 were dispersed during 3 to 4 min. with 10ml of trypsin - EDTA, which was added with 15mM of a HEPES solution to adjust the pH to 7.4. When the cells were completely detached, the dispersion was stopped with 1ml CFS and those were centrifuged 5 min. at 800g in a table centrifuge. The residue was resuspended in DMEM, a 50ul aliquot of cells was mixed well with 10ml of Isoton II™ contained in a counting cupule. From this mix a 500ul volume is counted using a Coulter Counter ZM™ which the counting bounds have been set previously. The cells were inseminated to a density corresponding to 80000 cells/ml of DMEM, 10% CFS, 1% penicillin-streptomycin.

Under agitation using a magnetic bar contained in a sterile bottle, 1ml of medium containing the cells were added to each well of a 12-well plate using a repetition pipette and a 50 ml sterile conical tube.

The plates were incubated at 37°C, 5% CO₂ and 100% humidity during 18 hours in an incubator.

Day 0: After having adhered, the cells are washed with DMEM medium heated at 37°C. The medium was then withdrawn by vacuuming. Then, 1ml of washing medium was added to each well with a serological polystyrene pipette of 10ml and withdrawn again by vacuuming. To each well, 900ul of experimental medium containing DMEM, 0.5% CFS and 1% of penicillin-streptomycin was precisely added with an automatic pipette of 100ul. Furthermore 100ul of a sample concentrated 10X was added using an automatic pipette of 100ul. Each plate included 3 samples and 1 negative control (basal level) effected in triplicate. For each sample, a serial dilution was executed in the experimental medium in sterile tubes of 3ml as follows.

	For 80ul/ml final:	1) 800ul sample + 200ul experimental medium
20	40ul/ml final:	2) 500ul solution 1) + 500ul experimental medium
	20ul/ml final:	3) 500ul solution 2) + 500ul experimental medium
25	Control:	DMEM + 0.5% CFS + 1% penicillin-streptomycin

Also, a positive control of 100ul CFS was added to the medium contained in the wells, as well as a stimulation control of a sample standard, were effected to verify the assay.

In order to see the progression of cellular proliferation, wells of positive and negative controls were effected on day 0 and day 1. The cellular dispersion method is described for day 2 below.

Day 2: The dispersion of cells was also effected with trypsin-EDTA previously equilibrated for 18 hours at 37°C under 5% CO₂. The medium was with-

drawn by vacuuming, then the cells were washed with 1ml of DMEM medium heated at 37°C. After having vacuumed the washing medium, 1 ml of trypsin maintained at 37°C is added in the wells. The cells detachment was
5 observed with a microscope. When the cells were completely loose, the dispersion was stopped by adding 100ul of CFS.

The cells were suspended by three successive reversal with a glass serological pipette of 5ml. The
10 suspension was transferred, by carefully taken each bubbles, in 7ml of Isoton II™ contained in a counting cupule. The well was then rinsed by three successive reversal with 2ml Isoton II™ and added to the previous 7ml. Before counting, the Isoton II™ containing the
15 cells was mixed well 5 times, with a serological polystyrene pipette of 10ml, in the cupules. A 500ul volume of the mix was counted using a Coulter Counter™ with the counting bounds previously set.

20 Experimental protocol of the measurement of the metabolic activity

Day 1: The assay was effected with Fibroblasts at passage 4. Thus, the fibroblasts which have come to passage 3 were dispersed during 3 to 4 min. with 10ml
25 of trypsin-EDTA, which was added with 15mM of a HEPES solution to adjust the pH to 7.4. When the cells were completely detached, the dispersion was stopped with 1ml CFS and those were centrifuged 5 min. at 800g in a table centrifuge. The residue was resuspended in DMEM,
30 a 50ul aliquot of cells was mixed well with 10ml of Isoton II™ contained in a counting cupule. From this mix, a 500ul volume is counted using a Coulter Counter ZM™ which counting bounds which have been set previously. The cells were inseminated to a density
35 corresponding to 8500 cells/200ul of DMEM, 10% CFS, 1% penicillin-streptomycin.

Under agitation using a magnetic bar contained in a sterile bottle, 200ul of medium containing the cells were added to each well of a 96-well plate using a multichannel pipette, while leaving the outside wells empty and the penultimate row free for the reaction blank. The plates were incubated at 37°C, 5% CO₂ and 100% humidity during 18 hours in an incubator.

Day 0: After having adhered, the cells are washed with DMEM medium heated at 37°C. The medium was then withdrawn by vacuuming. Then, 1ml of washing medium was added to each well and withdrawn again by vacuuming. To each well, 90ul of experimental medium containing DMEM, 0.5% CFS and 1% of penicillin-streptomycin was precisely added with a multichannel pipette. Furthermore 10ul of a sample concentrated 10X was added using an automatic pipette of 10ul. Each plate included 5 samples of 3 dosages, 1 negative control (basal level) and 1 positive control (10ul of CFS was added to each 90ul medium present in each well. These were all effected in triplicate. Within the samples, a stimulation control of a standard sample is effected in order to verify the validity of the assay. For each sample, a serial dilution was executed in the experimental medium in sterile tubes of 3ml as follows.

25	For 80ul/ml final:	1) 800ul sample + 200ul experimental medium
	40ul/ml final:	2) 500ul solution 1) + 500ul experimental medium
30	20ul/ml final:	3) 500ul solution 2) + 500ul experimental medium
	Control:	DMEM + 0.5% CFS + 1% penicillin-streptomycin

35

In order to see the progression of cellular proliferation, wells of positive and negative controls

were effected on day 0 and day 1. Th method of treatment is described for day 2 below.

Day 2: After a two-day incubation, 25ul of MTT reactant (5mg/ml concentration) was added to 100ul medium in each well. This must be effected without any light. The plates are then return to incubate in the dark at 37°C for at least two hours. Then, 100ul of lysing buffer were added to each well, and left to incubate for 18 hours in the dark at 37°C. The next day, the 96-well plates were read using a ELISA spectrophotometer at a wavelength of 470 nm and having previously determined the reaction blank pattern.

Preparation of MTT reactant

Concentration: 5mg/ml (for 100ml weight 500mg)
500mg MTT/100ml PBS
filtered on 0.22mm

Store at 4°C in a brown bottle away from the light. Can be store up to one month.

Lysing buffer

For 200ml prepare:

50% DMF = 105ml DMF + 105ml H₂O
20% SDS = 40g SDS + 180ml DMF 50%

The pH was adjusted at 4.7 with acetic acid (80%) 2.5% HCl (5ml HCl 1N + 5ml acetic acid 80%).

Completed to 200ml with DMF 50%.

Platelets α granules are the richest in vivo source of TGF β and PDGF. Porcine platelets contain two isotypes, TGF β 1 and β 2. Human and porcine TGF β 1 have total sequence identity and TGF β 2 has approximately 70% homology with TGF β 1. All TGF β s are naturally found as a latent, high molecular weight, inactive complexes in platelets. In the platelet extracts of the present invention, the measurement of non-extracted and acid-extracted platelet extracts yielded the same amount of TGF β 1 and β 2, indicating that TGF β 1 and β 2

are present in our extracts in its active form of about 25 KD.

PDGF is a disulfide-linked dimer with a molecular weight 30-32 KD. The subunits of the dimer are two related polypeptides designated the A and B chains. Although human platelet PDGF has been shown to consist of PDGF-AB and PDGF-BB, porcine platelet PDGF consists primarily of PDGF-BB homodimers. Because of its higher affinity for the type B PDGF receptor, PDGF-BB is more potent than PDGF-AB in stimulating cell proliferation *in vitro*. However, *in vivo* data suggest that PDGF AB and BB have equal potency as wound healing enhancers.

Both PDGF and TGF β s are known as stimulators of wound healing. They both induce extracellular matrix synthesis, granulation tissue formation and increase wound breaking strength in a variety of animal models. Both recombinant TGF β 1 and β 2 and PDGF-BB are currently tested in clinical trials as therapeutic agents for the healing of chronic ulcers with promising initial results.

In addition to PDGF and TGF β , platelet α granules have been shown to contain a number of agents that might play a role in the process of wound healing. Among these substances are Platelet Factor 4 (PF4), a platelet-derived Endothelial Cell Growth Factor (pdECGF), an Epidermal Growth Factor-like protein (EGF), and traces of IGF-I, IGF-II and IGFBP3.

Thus, the analytical results showed that the process of extraction in accordance with the present invention successfully recovered PDGF and TGF β from platelets.

In cell culture, the platelet extracts of the present invention stimulated fibroblast proliferation in a dose dependent manner. PE induced a dose-depend-

ent increase of porcin primary cultured fibroblasts (PPCF).

Recently, a randomized, double blind and placebo clinical study reported significant improvements in diabetic ulcers treated with an homologous human platelet lysate derived from pooled human platelets. Moreover, a cost-efficacy analysis conducted for this study revealed that the treatment was associated with a 38% decrease in the medical costs when compared to a conventional therapy. Although the composition of the PE of the present invention differs from that of the human platelet lysate (thrombin activated platelet wound healing formula) developed by Curative Technologies Inc., the results of this study illustrate the therapeutic potential and the advantages of growth factor extracts over recombinant growth factors.

The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.

EXAMPLE I

Porcine platelet extracts prepared in accordance with the present invention as compared to the extracts of the Knighton procedure

Porcine platelet extracts of the present invention

The platelet extracts were prepared according to the procedure described above and as illustrated in Fig. 1, but with the following distinctions.

Extracts: EP-95-11

The platelet residue was removed from the supernatant and was resuspended at 1×10^{10} platelets/ml in picopure water at 4°C. This was frozen in thin layers using liquid nitrogen, and then lyophilized.

Extract: EP-PL-LYTE

The platelet residue was removed from the supernatant and was resuspended at 1×10^{10} platelets/ml in Plasma-Lyte™ at 4°C. This was frozen in thin layers using liquid nitrogen, and then lyophilized.

Knighton porcine platelet extracts

The platelet extracts of Knighton, as illustrated in Fig. 2, were used to serve as a comparison with the platelet extracts of the present invention. The Knighton procedure is a known method published by Knighton et al. (Ann. Surg., 1986, 204: 322-330).

A. Pig preparation

A pig of 20-28kg was injected intramuscularly in its hindside region with 4-5ml Ketaset™. After 5 to 10 min., the pig was weighed and anaesthetized with fluothane. The pig was placed on its back with its legs attached to the anesthetic table. Then, the tracheotomy was made and the tracheal tube was introduced in the trachea and the balloon was inflated. The pig was connected to the mechanical respirator. The carotid was cleared. A catheter was introduced in the carotid, which was connected to a two-way faucet and to a septum. Before animals were exsanguinated, about 2 ml of heparin saline was injected in the cannula system and the same volume was vacuumed out.

B. Blood collection

Blood was collected using a 60ml syringe containing 12ml of acid-citrate-dextrose buffer.

C. Platelet-rich-plasma preparation

The collected sterile whole porcine blood was centrifuged in 450ml bottles for about 3 min. at 1600g

and 22°C (BRAKE=maximum; Beckman™ J2-21). The supernatant, platelet-rich-plasma (PRP), was transferred in 450ml bottles.

5 **D. Preparation of the platelet concentrate**

The collected platelet-rich-plasma (PRP) was immediately centrifuged for about 20 min. at 1600g and 22°C (BRAKE=6; Beckman™ J2-21). The platelet-poor-plasma (PPP) was discarded.

10

E. Washing of the platelet concentrate

The red blood cells residue was resuspended in PBS buffer (pH 7.4) to obtain a platelet concentration of 10^9 platelets/ml. Centrifuged in 450ml bottles for about 20 min. at 1600g and 22°C (BRAKE=6; Beckman™ J2-21).

15

The residue was resuspended in PBS buffer (pH 7.4) to obtain a platelet concentration of 1×10^{10} platelets/ml.

20

F. Method of activation of the platelets

10µg/ml of thrombin was added to the platelets and incubated for 30 min. between 0°C and 4°C. The platelets were centrifuged in 450ml bottles for about 5 min. at 950g and 4°C (BRAKE=6; Beckman™ J2-21).

25

The supernatant containing the granules is aliquoted in 2ml tubes and stored at -80°C.

Table 1

30 **Comparative evaluation of porcine platelet extracts**

Extracts	Porcine Weight (kg)	Proteins mg/ml	Albumin µg/ml	Alb/Prot %	TGF-β1 ng/ml	PDGF ng/ml	Thbs µg/ml	FbN µg/ml
PTRF (Knighton)	26	1.9	188	9.9	151	81	2.9	5.6
EP-95-11	37	6.6	40	0.6	169	171	10.2	13.1
EP-PL-LYTE	27.5	9.2	36.9	0.4	217	269	17.4	20.1

It can be seen in Table 1 that the platelet extract EP-95-11 produced by the process of the present invention, which consists in resuspension in pure water before a final step of lyophilization and further resuspension in pico pure water, resulted in an increased concentration of PDGF, TGF- β 1, thrombospondin (Thbs), and fibronectin (FbN) as compared to the Knighton extract (PTRF). But, most importantly, the platelet extract EP-95-11 contains only traces of albumin with respect to its protein content when compared with the PTRF of Knighton.

Furthermore, the platelet extract EP-PL-LYTE produced by the process of the present invention, which consists in resuspension in Plasma-Lyte™ before a final step of lyophilization, in order to further preserve the integrity of the platelets, and resuspend in pico pure water, resulted in a even more increased concentration of PDGF, TGF- β 1, thrombospondin (Thbs), and fibronectin (FbN) as compared to the Knighton extract (PTRF). But, most importantly, the platelet extract EP-95-11 contains even lower traces of albumin with respect to its protein content as compared to the PTRF of Knighton and even the platelet extract EP-95-11.

Table 2

In vitro bioactivity of porcine platelet extracts on primary culture fibroblasts

Extracts	Porcine Weight kg	Proliferation(%) / Control			MTT (%) / Control		
		20ul	40ul	80ul	20ul	40ul	80ul
PTRF (Knighton)	26	134	146	205	187	206	209
EP-95-11	37	153	234	355	200	236	264
EP-PL-LYTE	27.5	198	272	366	255	284	300

It can be seen in Table 2 that the platelet extract EP-95-11 of the present invention resulted in a more effective proliferation and a 3 to 4-fold increase in MTT as compared to the PTRF extract of Knighton.

5 Furthermore, the platelet extract EP-PL-LYTE, resulted in even more effective proliferation and more than 10-fold increase in MTT as compared to the PTRF extract of Knighton.

10 Thus, the lyophilization step permits the easy storage of the extract and a lengthened shelf life. The Plasma Lyte with the lyophilization allows for the preservation of the active principles in a non-denatured form (matured) and result in an increased concentration of the growth factors in each ml of
15 extract.

Figs. 3 illustrates the elution profile on column Protein Pak SW™ (8.0 x 300) of different molecular weight markers. Figs. 4 to 6 illustrate the results of a comparative analysis of elution profiles of the PTRF
20 extract of Knighton as compared to EP-95-11 and EP-PL-LYTE platelet extracts of the present invention. These elution profiles were conducted on column Protein Pak SW™ (8.0 x 300).

25 Figs. 7 to 10 illustrates a further comparative analysis of elution profile conducted on a different column YMC-Pak Column Diol-120™.

It can be seen from these comparative analyses that the extracts of the present invention show a higher concentration of the growth factors, based on
30 direct measurements, which could explain the higher activity found in Table 2. Also, in both column systems, the concentration of proteins and growth factors is much higher than for the extract obtained by the process of Knighton.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

WE CLAIM:

1. A process for the preparation of porcine platelet-extract containing matured growth factors, thrombospondin, fibronectin and minimal albumin, which comprises the steps of:

- a) centrifuging whole porcine blood at about 1000g to about 5000g to isolate the platelets from the platelet-rich-plasma;
 - b) resuspending the isolated platelets of step a) in Plasma-Lyte A and centrifuging to concentrate said platelets;
 - c) washing said concentrated platelets of step b);
 - d) lyophilizing said washed platelets of step c);
- whereby causing lysis of said platelets and producing the platelet extract.

2. The process of claim 1, which further comprises a step of resuspension after step d), wherein said lyophilized platelets are resuspended.

3. The process of claim 2, wherein said resuspension is effected in pure water.

4. The process of claim 1, wherein said washing of step c) is effected in pure water or in Plasma-Lyte A.

5. A pharmaceutical composition for promoting wound healing, which comprises an effective concentration of a platelet extract prepared according to the process of claim 1, wherein said platelet extract contains matured growth factors, thrombospondin, fibronectin and minimal albumin; in association with a pharmaceutically acceptable carrier


6. The pharmaceutical composition of claim 5, wherein said platelet extract concentration is between 10^7 to 10^{12} platelet equivalent/ml.


7. The use of the composition of claim 5 for the promotion of wound healing of a patient.

8. A porcine platelet-extract prepared according to the process of claim 1, which comprises matured growth factors, thrombospondin, fibronectin and traces of albumin proteins.


1/11

FILE - 1A






3/11




4/11




FIS-3


5/11




6/11

FIG. 5


7/11

FIG. 6

8/11


FIG. 7

9/11




FIS - B

10/11



FIS-9

11/11

FIG. 10

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/CA 97/00188

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K35/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 15763 A (UNIV MONTREAL) 15 June 1995 see page 12, line 10 - page 14, line 15; claims 1,5,11,12; examples I-VI	1-8
A	WO 86 03122 A (CURATECH INC) 5 June 1986 see page 4, line 23 - page 6, line 18; claims; examples	1,5,7,8
A	DATABASE WPI Section Ch, Week 8739 Derwent Publications Ltd., London, GB; Class B04, AN 87-273786 XP002032882 & JP 62 190 128 A (NIPPON CHEM RES KK) , 20 August 1987 see abstract	1,5

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

12 June 1997

Date of mailing of the international search report

25.06.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Fuhr, C

INTERNATIONAL SEARCH REPORT

Inter. Appl. Application No

PCT/CA 97/00188

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 22, no. 5 PT 1, May 1990, pages 781-791, XP000674706 G.A. KSANDER ET AL.: "The effect of platelet releasate on wound healing in animal models" see page 782, left-hand column, paragraph 4 - right-hand column, paragraph 3 see page 788, left-hand column, paragraph 3 - page 790, right-hand column, paragraph 1</p> <p>-----</p>	1,5,7,8

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 97/00188

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 7
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although this claim is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

Intern al Application No

PCT/CA 97/00188

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9515763 A	15-06-95	AU 7988594 A	27-06-95
WO 8603122 A	05-06-86	AU 596954 B	24-05-90
		AU 5094985 A	18-06-86
		CA 1261259 A	26-09-89
		CH 673774 A	12-04-90
		DE 3586355 A	20-08-92
		DE 3590594 T	29-01-87
		EP 0202298 A	26-11-86
		EP 0383363 A	22-08-90
		GB 2248777 A,B	22-04-92
		JP 7020873 B	08-03-95
		JP 62501628 T	02-07-87
		NL 8520384 T	29-11-84
		SE 8603228 A	25-07-86
		US 4957742 A	18-09-90
		US 5178883 A	12-01-93
		US 5165938 A	24-11-92